Acucela Announces Publication of Pre-clinical Data for Emixustat Hydrochloride
SEATTLE--(BUSINESS WIRE)--Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of pre-clinical data related to the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal Investigative Ophthalmology & Visual Science (IOVS). The published article, “Emixustat reduces metabolic demand of dark activity in the retina,”